CASI Pharmaceuticals Inc./$CASI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Ticker
$CASI
Sector
Primary listing
Employees
233
Headquarters
Website
CASI Metrics
BasicAdvanced
$37M
-
-$2.87
0.61
-
Price and volume
Market cap
$37M
Beta
0.61
52-week high
$3.09
52-week low
$1.09
Average daily volume
2.5M
Financial strength
Current ratio
0.481
Quick ratio
0.321
Total debt to equity
-92.24
Interest coverage (TTM)
-44.50%
Profitability
EBITDA (TTM)
-39.761
Gross margin (TTM)
41.03%
Net profit margin (TTM)
-148.56%
Operating margin (TTM)
-131.12%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-62.73%
Return on equity (TTM)
830.72%
Valuation
Price to revenue (TTM)
1.224
Price to book
-1.8
Price to tangible book (TTM)
-1.78
Growth
Revenue change (TTM)
36.64%
Earnings per share change (TTM)
41.19%
3-year revenue growth (CAGR)
-3.30%
10-year revenue growth (CAGR)
83.88%
3-year earnings per share growth (CAGR)
7.13%
10-year earnings per share growth (CAGR)
-10.44%
CASI News
AllArticlesVideos
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
Accesswire4 days ago
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
Accesswire1 week ago
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
Accesswire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CASI Pharmaceuticals Inc. stock?
CASI Pharmaceuticals Inc. (CASI) has a market cap of $37M as of September 12, 2025.
What is the P/E ratio for CASI Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for CASI Pharmaceuticals Inc. (CASI) stock is 0 as of September 12, 2025.
Does CASI Pharmaceuticals Inc. stock pay dividends?
No, CASI Pharmaceuticals Inc. (CASI) stock does not pay dividends to its shareholders as of September 12, 2025.
When is the next CASI Pharmaceuticals Inc. dividend payment date?
CASI Pharmaceuticals Inc. (CASI) stock does not pay dividends to its shareholders.
What is the beta indicator for CASI Pharmaceuticals Inc.?
CASI Pharmaceuticals Inc. (CASI) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.